{"id":"NCT03125395","sponsor":"Vertex Pharmaceuticals Incorporated","briefTitle":"A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation","officialTitle":"A Phase 3, Rollover Study to Evaluate the Safety of Long-term Treatment With Lumacaftor/Ivacaftor Combination Therapy in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-05-12","primaryCompletion":"2019-07-17","completion":"2019-07-17","firstPosted":"2017-04-24","resultsPosted":"2020-08-07","lastUpdate":"2020-08-07"},"enrollment":57,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cystic Fibrosis"],"interventions":[{"type":"DRUG","name":"LUM/IVA","otherNames":["VX-809/VX-770","lumacaftor/ivacaftor"]}],"arms":[{"label":"LUM/IVA","type":"EXPERIMENTAL"}],"summary":"A Rollover Safety Study of Lumacaftor/Ivacaftor in Subjects Aged 2 Years and Older With Cystic Fibrosis, Homozygous for F508del.","primaryOutcome":{"measure":"Safety as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)","timeFrame":"Day 1 up to Week 98","effectByArm":[{"arm":"LUM/IVA","deltaMin":56,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":8},"locations":{"siteCount":20,"countries":["United States","Canada"]},"refs":{"pmids":["33965000"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":57},"commonTop":["Cough","Nasal congestion","Pyrexia","Rhinorrhoea","Vomiting"]}}